Description

CYRA TAB (1X10)

Indications

CYRA TAB is primarily indicated for the treatment of various gastrointestinal disorders, including gastroesophageal reflux disease (GERD), peptic ulcers, and Zollinger-Ellison syndrome. It is often prescribed to alleviate symptoms such as heartburn, acid regurgitation, and discomfort associated with excessive stomach acid production. The formulation is designed to provide effective relief and promote healing of the gastrointestinal mucosa.

Mechanism of Action

The active ingredient in CYRA TAB functions as a proton pump inhibitor (PPI). It works by irreversibly inhibiting the H+/K+ ATPase enzyme system at the gastric parietal cells. This action significantly reduces gastric acid secretion, leading to decreased acidity in the stomach and duodenum. By lowering acid levels, CYRA TAB helps in healing erosive esophagitis and alleviating symptoms of acid-related disorders.

Pharmacological Properties

CYRA TAB exhibits a rapid onset of action, typically beginning to work within one hour of administration, with peak effects occurring within 2 to 4 hours. The drug has a half-life of approximately 1 to 2 hours, but its effects may last longer due to the irreversible nature of its action on the proton pump. The bioavailability of CYRA TAB is influenced by food intake, and it is recommended to take the medication on an empty stomach for optimal absorption. The drug is metabolized primarily in the liver and excreted through the urine.

Contraindications

CYRA TAB is contraindicated in patients with known hypersensitivity to the active ingredient or any of the excipients in the formulation. It should also be avoided in individuals with severe liver impairment, as this may lead to increased systemic exposure and potential toxicity. Additionally, the use of this medication is not recommended during pregnancy unless the benefits outweigh the risks, and it should be avoided in breastfeeding mothers due to potential effects on the infant.

Side Effects

Common side effects associated with CYRA TAB include headache, diarrhea, constipation, nausea, and abdominal pain. These effects are generally mild and transient. However, more serious adverse reactions may occur, including allergic reactions, liver enzyme elevations, and gastrointestinal infections such as Clostridium difficile colitis. Long-term use of proton pump inhibitors has been associated with an increased risk of bone fractures, renal impairment, and vitamin B12 deficiency. Patients should be monitored for these potential complications, especially with prolonged therapy.

Dosage and Administration

The recommended dosage of CYRA TAB varies based on the specific condition being treated. For GERD, the typical starting dose is 20 mg once daily, which may be adjusted based on the patient’s response and the severity of the condition. For peptic ulcers, a higher dose of 40 mg may be prescribed. It is crucial to adhere to the prescribed regimen and not to exceed the recommended dosage. CYRA TAB should be taken whole with water, preferably 30 minutes before a meal to enhance its effectiveness.

Interactions

CYRA TAB may interact with several medications, potentially altering their effectiveness or increasing the risk of adverse effects. Notable interactions include those with anticoagulants such as warfarin, as well as drugs that require an acidic environment for absorption, such as certain antifungals and antiretrovirals. It is essential for patients to inform their healthcare provider of all medications they are taking, including over-the-counter drugs and supplements, to avoid potential interactions. Monitoring may be necessary when initiating or discontinuing CYRA TAB in patients on concurrent medications.

Precautions

Patients should use CYRA TAB with caution if they have a history of liver disease, kidney disease, or osteoporosis. Regular monitoring of liver function tests and renal parameters is advisable during treatment. Additionally, long-term use of proton pump inhibitors should be evaluated periodically to assess the need for continued therapy. Patients should be advised to report any unusual symptoms or side effects to their healthcare provider promptly. Special consideration should be given to the elderly population, who may be more susceptible to side effects and drug interactions.

Clinical Studies

Clinical studies have demonstrated the efficacy of CYRA TAB in managing acid-related disorders. In a randomized controlled trial involving patients with GERD, those treated with CYRA TAB showed significant improvement in symptom relief compared to placebo. Another study highlighted the drug’s effectiveness in promoting healing of peptic ulcers, with a notable reduction in ulcer recurrence rates. These findings support the use of CYRA TAB as a valuable therapeutic option for patients suffering from excessive gastric acid production and related conditions.

Conclusion

CYRA TAB is an effective proton pump inhibitor indicated for the treatment of various gastrointestinal disorders characterized by excessive gastric acid production. With its mechanism of action focused on reducing acid secretion, it provides symptomatic relief and promotes healing of the gastrointestinal lining. While generally well-tolerated, it is essential to be aware of potential side effects, contraindications, and drug interactions. Patients should engage in open communication with their healthcare providers to ensure safe and effective use of CYRA TAB.